Pierone G, Schulman K, Fusco J, et al. Characteristics of Early Adopters of a Two-Drug Regimen (Dolutegravir/Lamivudine) for Treatment of Human Immunodeficiency Virus Type 1 (HIV-1) in a Real-World Setting. Presented at: ACTHIV 2020; Virtual Meeting.
Research Category: Abstracts and Posters
Clinical outcomes of heavily treatment experienced individuals in the OPERA Cohort
Hsu R, Fusco J, Henegar C, et al. Clinical outcomes of heavily treatment experienced individuals in the OPERA Cohort [PEB0234]. Presented at: The 23rd International AIDS Conference (AIDS 2020) 2020; Virtual Meeting
To Dose-Adjust or Not to Dose-Adjust: 3TC Dose in Renal Impairment
Mounzer K, Brunet L, Wyatt C, et al. To Dose-Adjust or Not to Dose-Adjust: 3TC Dose in Renal Impairment. Presented at: The 23rd International AIDS Conference (AIDS 2020) 2020; Virtual Meeting. San Francisco
To Dose-Adjust or Not to Dose-Adjust: 3TC Dose in Renal Impairment
Mounzer K, Brunet L, Wyatt C, et al. To Dose-Adjust or Not to Dose-Adjust: 3TC Dose in Renal Impairment. Paper presented at: 24th International Workshop on HIV and Hepatitis Observational Database (IWHOD) 2020; Meeting Canceled (COVID-19)
EASL Biomarkers Differ in Predicting NAFLD, NASH, & Fibrosis in HIV(+)/(-) Individuals
Hsu R, Brunet L, Fusco J, Fusco G. EASL Biomarkers Differ in Predicting NAFLD, NASH, & Fibrosis in HIV(+)/(-) Individuals. Presented at: Conference on Retroviruses and Opportunistic Infections (CROI) 2020; Boston, MA, USA
2-Drug Regimen Comparable to 3-Drug Regimens up to 18 Months in a Real-World Setting
Pierone G, Schulman KL, Fusco J, et al. 2-Drug Regimen Comparable to 3-Drug Regimens up to 18 Months in a Real-World Setting. Presented at: CROI 2020; Boston, MA, USA
Outcomes in 960 individuals with triple infection with HIV, chronic hepatitis B, and chronic hepatitis C
Russo M, Fusco J, Dieterich D, Brunet L, Fusco G. Outcomes in 960 individuals with triple infection with HIV, chronic hepatitis B, and chronic hepatitis C. Presented at: AASLD 2019; Boston, MA, USA
Loss of surface antigen in HIV/HBV co-infected individuals
Dieterich D, Fusco J, Russo M, Brunet L, Fusco G. Loss of surface antigen in HIV/HBV co-infected individuals. Presented at: AASLD 2019; Boston, MA, USA
Changes in LDL After Switch from TDF to TAF in the U.S
Mallon P, Brunet L, Fusco J, et al. Changes in LDL After Switch from TDF to TAF in the U.S. [PE2/44]. Presented at: 17th European AIDS Conference (EACS 2019); 6-9 November 2019, 2019; Basel, Switzerland.
Characterizations of weight gain following antiretroviral regimen initiation in treatment-naïve individuals living with HIV
Hsu R, Brunet L, Mounzer K, et al. Characterizations of weight gain following antiretroviral regimen initiation in treatment-naïve individuals living with HIV [PE2/32]. Presented at: European AIDS Conference (EACS) 2019; Basel, Switzerland